Lipids & metabolic liver disease
Safety and efficacy of bempedoic acid: a systematic review and meta-analysis of randomised controlled trials
Pooled result · MACEResult — go to the resultOdds ratio 0.86 95% CI 0.79–0.95Authors' conclusion
The improved cholesterol control achieved with BA translates into a reduced risk of MACE, including myocardial infarction and coronary revascularisation. The drug has a satisfactory safety profile except for an increased risk of gout.
Study context
- Population
- Patients with hypercholesterolemia; RCTs of Bempedoic Acid (BA) vs placebo (PubMed, Scopus, Cochrane library)
- Participants
- 18,315 patients11 studies
- Comparison
- Bempedoic acid 180 mg/die vs placebo/no treatment
- BAn = 9,854
- Placebo/no treatmentn = 8,461reference
- Outcome
- Major adverse cardiovascular events (MACE) (primary efficacy endpoint); LDL-C reduction (primary laboratory endpoint)
Pooled result
MACE · median follow up 87 (15-162) weeks
Odds ratio
0.86
95% CI 0.79–0.95
BAvs Placebo/no treatment
OR 0.86 (95% CI 0.79–0.95)
As reported in the abstract
Further pooled results
| Outcome | OR (95% CI) | |
|---|---|---|
| MI · median follow-up 87 (15-162) weeksBAvs Placebo | 0.76 (0.64–0.88) | |
| Unstable angina · median follow-up 87 (15-162) weeksBAvs Placebo | 0.69 (0.54–0.88) | |
| 0.512Odds ratio (log scale) |
| Outcome | Estimate |
|---|---|
| Total cholesterol · 12 weeksBA vs Placebo | - 16.50% (95% CI - 19.21% to - 13.79%) |
| Apo-B lipoprotein · 12 weeksBA vs Placebo | - 19.55% (CI - 22.68% to - 16.42%) |
| High-sensitivity CRP · 12 weeksBA vs Placebo | - 27.83% (CI - 31.71% to - 23.96%) |
Laboratory endpoints by background therapy
- Efficacy on laboratory endpoints confirmed, with variable extent, across patients on statin or ezetimibe background therapy
Safety
| Outcome | OR (95% CI) | |
|---|---|---|
| Gout | 1.55 (1.27–1.90) | |
| 0.512Odds ratio (log scale) |
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Safety and efficacy of bempedoic acid: a systematic review and meta-analysis of randomised controlled trials. Cardiovasc Diabetol. Published 28 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →